Comparison of cutaneous silent period parameters in patients with primary Sjogren's syndrome with the healthy population and determination of its relationship with clinical parameters

YOLCU G., Abacar K. Y., Kenis-Coskun O., Nevsun-Inanc G., Karadag-Saygi E., Gunduz O. H.

RHEUMATOLOGY INTERNATIONAL, cilt.43, sa.2, ss.355-362, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 43 Sayı: 2
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1007/s00296-022-05198-x
  • Dergi Adı: RHEUMATOLOGY INTERNATIONAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.355-362
  • Anahtar Kelimeler: Electrophysiology, Neurologic Manifestations, Sjogren's Syndrome, Small Fiber Neuropathy, SMALL-FIBER NEUROPATHY, CENTRAL SENSITIZATION, MANIFESTATIONS, FIBROMYALGIA, CRITERIA, SYMPTOMS
  • Marmara Üniversitesi Adresli: Evet

Özet

Small fiber neuropathy (SFN) is one of the main neurological manifestations in primary Sjogren's Syndrome (pSS). For the detection of SFN, cutaneous silent period (CSP) measurement is gaining popularity recently due to its non-invasiveness and practical application. Evaluating SFN involvement in patients with pSS using CSP and evaluating its relationship with clinical parameters. Patients with a diagnosis of pSS and healthy volunteers demographically homogeneous with the patient group were included in the study. The CSP responses were recorded over the abductor pollicis brevis muscle. The latency and duration values of the responses were obtained. In patient group, EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI), Hospital Anxiety and Depression Scale (HADS), Short Form-36 (SF-36) questionnaire, Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) and Central Sensitization Inventory (CSI) were applied for the evaluation of symptom severity, mood, quality of life, presence of neuropathic pain and central sensitization, respectively. The mean CSP latency was significantly longer in patient group compared to control group (p < 0.001). Mean CSP duration was also significantly shorter in patient group (p < 0.001). There were no significant differences in CSP parameters according to patients' neuropathic pain or central sensitization profile. There were significant correlations of CSP parameters (latency and duration, respectively) with ESSPRI dryness (rho = 0.469, p = 0.004; rho = -0.553, p < 0.001), fatigue (rho = 0.42, p = 0.011; rho = -0.505, p = 0.002), pain (rho = 0.428, p = 0.009; rho = -0.57, p < 0.001) subscores and mean ESSPRI score (rho = 0.631, p < 0.001; rho = -0.749, p < 0.001). When SF-36 subscores and CSP parameters were investigated, a significant correlation was found only between "bodily pain" subscore and CSP duration (rho = -0.395, p = 0.017). In HADS, LANSS and CSI evaluations, a significant correlation was found only between HADS anxiety score and the CSP duration (rho = 0.364, p = 0.02). As indicated by CSP measurement, SFN is more prominent in patients with pSS than in the healthy population. It is important to investigate the presence of SFN because of its correlation with the leading symptoms in the clinical spectrum of pSS.